Alexander Schmitz is a partner at Endeavour Vision, investing in medical technology and digital health companies across multiple therapeutic areas.
Mr. Schmitz brings more than two decades of business and strategy experience in both medical device and high-technology companies. He currently represents Endeavour Vision on the boards of Lumeon, Kenbi, Rapid Micro Biosystems, Relievant, and VentureMed. He previously served on the boards of VertiFlex (acquired by Boston Scientific in 2019).
Prior to joining the Endeavour Vision team, Mr. Schmitz spent nine years with Biosensors International Group, an interventional cardiology company, where he served as vice president of business development. He previously worked with LogiSpring Ventures, MicroStrategy and McKinsey & Co.
Mr. Schmitz holds an MBA from INSEAD and a BSFS, magna cum laude, from Georgetown University.